Index

Show indicators by:

  • Cancer Control Domain
  • Disease Site
  • Dashboard
  • Disease Site
    • Breast
      • Breast cancer screening
      • Screening in underserved populations
      • Breast cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Breast cancer resections that are mastectomies
        • The use of breast-conserving surgery versus mastectomies for breast cancer resections
      • Radiation therapy
        • Post-operative radiation therapy for stage I or II breast cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Breast cancer screening outside recommended guidelines
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Colorectal
      • Colorectal cancer screening
      • Geographic variation in colorectal cancer risk
      • Screening in underserved populations
      • Colorectal cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Removal and examination of 12 or more lymph nodes in colon resections
        • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
      • Radiation therapy
        • Pre-operative radiation therapy for patients with stage II or III rectal cancer
      • Post-operative chemotherapy for stage III colon cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Lung
      • Capture of stage
      • Stage distribution
      • Geographic variation in lung cancer risk
      • Resection rates for stage II or IIIA Non-snmall cell lung cancer patients
      • Post-operative chemotherapy for stage II or IIIA non-small cell lung cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Prostate
      • PSA testing
      • Prostate risk profile
      • Capture of stage
      • Stage distribution
      • Prostate wait times for surgery
      • Prostate wait times for radiation therapy
      • Radical prostatectomy: open versus laparoscopic surgery
      • Prostate patterns of care: radiation and surgical treatment
      • Prostate access to palliative radiation
      • Prostate clinical trials participation
      • Adult clinical trial participation
      • Prostate cancer research investment
      • Cancer research investment
      • Incidence & Mortality Rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Cervical
      • Human papillomavirus (HPV) vaccination
      • Cervical cancer screening
      • Screening in underserved populations
    • Pancreas
      • Incidence and mortality rates
    • Stage Distribution
  • Province & Territory
  • 1. Prevention
  • 2. Screening
  • 3. Diagnosis
  • 4. Treatment
  • 5. Person-Centred Perspective
  • 6. Research
  • 7. Appropriateness
  • 8. Long-term outcomes
  • Smoking prevalence
  • Smoking behaviours in current cancer patients
  • Smoking cessation
  • Second-hand smoke exposure
  • Geographic variation in lung cancer risk
  • Alcohol consumption
  • Adult overweight and obesity
  • Active transportation
  • Physical inactivity
  • Human papillomavirus (HPV) vaccination
  • Fruit and vegetable consumption
  • Geographic variation in colorectal cancer risk
  • Cervical cancer screening
  • Breast cancer screening
  • Colorectal cancer screening
  • PSA testing
  • Screening in underserved populations
  • Breast cancer diagnosis wait times
  • Colorectal cancer diagnosis wait times
  • Capture of stage
  • Stage distribution
  • Prostate risk profile
  • Surgery
  • Radiation therapy
  • Systemic therapy
  • Removal and examination of 12 or more lymph nodes in colon resections
  • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
  • The use of breast-conserving surgery versus mastectomies for breast cancer resections
  • Breast cancer resections that are mastectomies
  • High-risk, resource-intensive surgeries for esophageal, pancreatic, liver, lung and ovarian cancers in Canada
  • Prostate wait times for surgery
  • Radical prostatectomy: open versus laparoscopic surgery
  • Radiation therapy wait times
  • Radiation therapy utilization and capacity
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer
  • Post-operative radiation therapy for patients with stage I or II breast cancer
  • Prostate wait times for radiation therapy
  • Prostate patterns of care: radiation and surgical treatment
  • Post-operative chemotherapy for stage III colon cancer patients
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer
  • Screening for distress
  • Patient satisfaction
  • Place of death
  • Prostate access to palliative radiation
  • Adult clinical trial participation
  • Prostate clinical trials participation
  • Pediatric clinical trial participation
  • Cancer research investment
  • Prostate cancer research investment
  • Breast cancer screening outside of guidelines
  • Breast cancer mastectomies done as day surgery
  • Intensive care use in the last two weeks of life
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Pancreatic cancer
  • Five-year net survival by income quintile for several cancers in Canada
System Performance Logo
System Performance
  • About
  • Reports
  • Français
  • Home
  • Disease sites
  • Colorectal
  • Radiation therapy
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer

Pre-operative radiation therapy for patients with stage II or III rectal cancer

  • Charts and Tables

    Charts and Tables

    Figure 4.14

    Percentage of Stage II or III rectal cancer patients who received radiation therapy before surgery, by jurisdiction — 2011 to 2014 diagnosis years

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    “—” Data not available.

    Data source: Provincial cancer agencies or programs.

    Data Table

    JurisdictionYearNumber of patients receiving radiation therapyPercent (%)Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    BC201118454.449.059.8
    BC201220155.850.561.0
    BC201321456.050.961.1
    BC2014----
    AB201115460.954.666.9
    AB201215159.252.965.3
    AB201313156.750.163.2
    AB201413353.647.260.0
    SK2011----
    SK2012----
    SK2013----
    SK2014----
    MB20116050.441.159.7
    MB20126458.248.467.5
    MB20136054.144.363.6
    MB20145557.346.867.3
    ON2011----
    ON2012----
    ON2013----
    ON2014----
    QC2011----
    QC2012----
    QC2013----
    QC2014----
    NB20113050.837.564.1
    NB20122850.937.164.6
    NB20133455.742.468.5
    NB20143152.539.165.7
    NS20114547.437.057.9
    NS20126056.646.666.2
    NS20134952.742.163.1
    NS20145556.145.766.1
    PE2011666.729.992.5
    PE2012650.021.178.9
    PE2013975.042.894.5
    PE20141164.738.385.8
    NL20113063.848.577.3
    NL20122659.143.273.7
    NL20132350.034.965.1
    NL20142852.838.666.7
    YT2011----
    YT2012----
    YT2013----
    YT2014----
    NT2011----
    NT2012----
    NT2013----
    NT2014----
    NU2011----
    NU2012----
    NU2013----
    NU2014----

    + Expand Table

    “—” Data not available.

    Data source: Provincial cancer agencies or programs.

  • Data specifications

    Data specifications

    Definition: The percentage of stage II or III rectal cancer cases receiving pre-operative radiation therapy up to 120 days before resections within one year of diagnosis

    Rationale for measurement: The delivery of radiation therapy (along with chemotherapy) prior to surgical resection for Stage II and III rectal cancer has been shown to improve local disease control compared with surgery alone or post-operative radiation therapy. Also, it has been associated with a reduction in treatment-related toxicity compared with post-operative radiation therapy. Clinical practice guidelines therefore recommend pre-operative radiation therapy (combined with chemotherapy) for patients with Stage II and III rectal cancer.

    Measurement timeframe: Diagnoses years 2011 to 2014

    Denominator: Stage II and III rectal cancer cases diagnosed during the timeframe and receiving rectal resection within one year of diagnosis

    Numerator: Stage II and III rectal cancer cases diagnosed during the timeframe and receiving pre-operative radiation therapy up to 120 days before resection within one year of diagnosis

    Exclusion criteria: Cases with age ≤ 17 were excluded

    Data availability:

    • 2011-2014: AB, MB, NB, NS, PE, NL
    • 2011-2013: BC

    Stratification:

    • By year
    • By province

    Data source: Provincial cancer agencies and programs

    Data retrieval date: October 2017

    Variables details:

    Cancer definition:

    1. Rectal cancer was defined as C20.9 in ICD-O3 with behavior code 3 (invasive)For cancer cases with lymphoma Codes M-95 to M-98, sarcoma codes (see Appendix A), neuroendocrine carcinoma and squamous cell carcinoma were excluded
    2. Rectal cancer cases were restricted to stage II and stage III in American Joint Committee on Cancer (AJCC).

    Resection identification:

    1. Rectal resections were identified in CCI codes as 1NQ87 or 1NQ89. CCI code 1NQ87BA was excluded.

    Treatment criteria:

    1. All rectal resections were within 1 year of diagnosis. If there were multiple resections, the first resection was counted:
      First resection date (if multiple) – diagnosis date ≤ 365 days
    2. All pre-operative radiation therapies were up to 120 days before resections. If there were multiple resections, the first resection was counted.
      First resection date – Radiation therapy date ≤120 days

    Notes from jurisdictions:

    • BC: We do not have surgery data past 2014 and since the indicator includes surgery up to 1 year following diagnosis, we cannot provide data for diagnosis year 2014.
    • NB: 2010/2011 radiation treatment may be incomplete.
    • PE: Did not have data on whether the resection margins were negative so cannot comment either way.

    Methodology notes:

    1. Data presented include stage II and III combined
    2. The cancer incidence sites/types were classified by World Health Organization, International Classification of Diseases for Oncology, Third Edition (ICD- O-3).
    3. American Joint Committee on Cancer (AJCC) Cancer Staging Manual 7th edition was used to classify cancer stage groups.
    4. The Canadian Classification of Health Interventions (CCI) codes were used to identify surgery types, except AB.

    Changes to definition compared to previous years: Resections with negative margin were not required.

  • Related indicators

    Related Indicators

    Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non–small cell lung cancer patients

    Percentage of Stage II or IIIA non-small cell lung cancer patients who had a surgical resection†, by province — from 2009 to 2012 diagnosis years
    View this indicator
    Radiation therapy utilization and capacity

    Number of linear accelerators per million people, by province – 2012 reporting year
    View this indicator
    Colorectal cancer

    Incidence and mortality rates† for colorectal cancer, by sex, Canada — from 1992 to 2014
    View this indicator
  • About Us
  • Careers
  • Contact
  • Media centre
  • Share your feedback
  • About our new site

  • Français Language toggle.

Other related sites:

  • Canadian Partnership for Tomorrow’s Health
  • Canadian Cancer Research Alliance
  • Canadian Cancer Trials
  • facebook
  • twitter
  • youtube
  • linkedin
    CPAC Logo

    Questions about cancer?

    For information about cancer treatment and support for patients, please contact the Canadian Cancer Society at 1-888-939-3333 or by completing this online form.

  • AODA compliance
  • Privacy policy
  • Terms of use
  • FAQ
  • Site map
  • About this site
© Canadian Partnership Against Cancer Corporation